drugset / Trial / NCT05764876
Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)
Phase 3
Completed
384 enrolled
Fight AIDS and Infectious Diseases Foundation
National Department of Health, Papua New Guinea · collabSchool of Medicine and Health Sciences, University of Papua New Guinea · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The goal of this clinical trial is to test the non inferiority of linezolid compared with azithromycin as a treatment for yaws . The main questions it aims to answer are: can linezolid cure active yaws, and can linezolid cure latent yaws. Participants with serologically confirmed yaws will be randomized to receive linezolid (experimental) or azithromycin (control group) treatment and followed up to assess clinical resolution.
Timeline
- Start
- 2023-03-14
- Primary completion
- 2024-06-20
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azithromycin | Small molecule | 30 mg/kg | Oral |
| Subject | Linezolid | Other / unclassified | 10 mg/kg | Oral |
| Subject | Linezolid | Other / unclassified | 600 mg | Oral |